本期精选3篇妇产科相关领域文章，对摘要进行了翻译，与妇产科同仁共读：
1.Olaparib plus Durvalumab, with or without Bevacizumab, as Treatment in PARP Inhibitor-Naïve Platinum-Sensitive Relapsed Ovarian Cancer: A Phase II Multi-Cohort Study
奥拉帕利联合度伐利尤单抗作为PARP抑制剂初治铂敏感复发性卵巢癌患者的治疗：一项II期多队列研究
2.Association of Continuous Glucose Monitoring Metrics With Pregnancy Outcomes in Patients With Preexisting Diabetes.
动态血糖监测指标与糖尿病患者妊娠结局的关联
3.Atezolizumab plus bevacizumab and chemotherapy for metastatic, persistent, or recurrent cervical cancer （BEATcc）: a randomised, open-label, phase 3 trial.
贝伐珠单抗联合化疗，同时加用阿替利珠单抗治疗转移性、持续性或复发性宫颈癌的3期临床试验
